AstraZeneca’s Airsupra asthma treatment shows breakthrough results in trial
Airsupra demonstrated a 47% reduction in the risk of severe exacerbations in mild asthma compared with albuterol alone.
AstaZeneca
Airsupra demonstrated a 47% reduction in the risk of severe exacerbations in mild asthma compared with albuterol alone.